Table 2.
Characteristics of patients who were and were not lost to follow up among treatment eligible or possibly eligible groups.
| Patient characteristics | Lost to follow up (n = 76) | Not lost to follow up (n = 156) | p-value * | Difference in proportions between were/were not lost to follow up (95% CI) | p-value ** |
|---|---|---|---|---|---|
| Age (years), median (IQR) | 58 (52–61) | 54 (48–59) | 0.173 | ||
| Male (%) | 50 (65.8) | 106 (68.0) | 0.742 | 0.02 (−0.11 to 0.15) | 0.742 |
| History of substance use (%) | 48 (68.6) | 107 (70.4) | 0.783 | −0.02 (−0.15 to 0.11) | 0.783 |
| Insured (%) | 69 (90.8) | 147 (94.2) | 0.332 | −0.03 (−0.11 to 0.04) | 0.336 |
| Hepatitis C virus genotype 1 (%) | 67 (94.4) | 142 (91.0) | 0.442 | 0.03 (−0.04 to 0.10) | 0.388 |
| Log10 HCV viral load (IU/mL), median (IQR) | 5.94 (5.40–6.42) | 5.98 (5.49–6.37) | 0.946 | ||
| Serum ALT (U/mL), median (IQR) | 51 (39–70) | 50 (37–80) | 1.000 | ||
| Fibrosis on liver histology or Fibrosure test (%)§ | 19 (63.3) | 62 (73.8) | 0.277 | −0.10 (−0.30 to 0.09) | 0.277 |
| Decompensated liver disease (%) | 3 (3.95) | 16 (10.3) | 0.127 | −0.06 (−0.13 to 0.00) | 0.098 |
| Treatment eligibility status (%) | |||||
| Eligible | 30 (39.5) | 150 (96.2) | <0.0001 | −0.57 (−0.68 to 0.45) | < 0.001 |
| Possibly eligible | 46 (60.5) | 6 (3.9) | |||
| ≥ 2 Medical comorbidities | 4 (5.26) | 23 (14.7) | 0.048 | −0.10 (−0.17 to −0.02) | 0.035 |
| History of psychiatric comorbidity | 32 (42.1) | 61 (39.1) | 0.661 | 0.03 (−0.10 to 0.16) | 0.661 |
| Direct acting antiviral agent availability | 27 (35.5) | 126 (80.8) | <0.0001 | −0.45 (−0.57 to −0.33) | < 0.001 |
ALT: alanine aminotransferase. IQR: interquartile range.
*
χ2 (Fisher’s exact when appropriate) or Mann-Whitney test, p-value < 0.05 considered statistically significant and bolded.
**
Z-test, p-value < 0.05 considered statistically significant (2-sided).
§
Liver biopsy performed for 93 patients, fibrosure performed for 46 patients, fibrosis defined as ≥ stage2. Loss to follow-up defined as not attending scheduled liver clinic visit while undergoing treatment eligibility evaluation or after being deemed eligible for treatment.